| Literature DB >> 24366229 |
Silvio Danese1, Laurent Peyrin-Biroulet2.
Abstract
In 2013, several new IBD drugs, including golimumab and vedolizumab, have been approved or completed successful programmes, showing efficacy in both Crohn’s disease and ulcerative colitis. In addition, classic IBD drugs have been formulated for colonic delivery, such as budesonide MMX®, which was recently approved for mild-to-moderate ulcerative colitis.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24366229 DOI： 10.1038/nrgastro.2013.246
Source DB: PubMed Journal: Nat Rev Gastroenterol Hepatol ISSN： 1759-5045 Impact factor: 46.802